1. Home
  2. ELVN vs FSCO Comparison

ELVN vs FSCO Comparison

Compare ELVN & FSCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • FSCO
  • Stock Information
  • Founded
  • ELVN 2016
  • FSCO 2013
  • Country
  • ELVN United States
  • FSCO United States
  • Employees
  • ELVN N/A
  • FSCO N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • FSCO Trusts Except Educational Religious and Charitable
  • Sector
  • ELVN Health Care
  • FSCO Finance
  • Exchange
  • ELVN Nasdaq
  • FSCO Nasdaq
  • Market Cap
  • ELVN 1.2B
  • FSCO 1.4B
  • IPO Year
  • ELVN 2020
  • FSCO N/A
  • Fundamental
  • Price
  • ELVN $22.63
  • FSCO $7.22
  • Analyst Decision
  • ELVN Strong Buy
  • FSCO
  • Analyst Count
  • ELVN 5
  • FSCO 0
  • Target Price
  • ELVN $41.20
  • FSCO N/A
  • AVG Volume (30 Days)
  • ELVN 721.5K
  • FSCO 709.7K
  • Earning Date
  • ELVN 08-12-2025
  • FSCO 01-01-0001
  • Dividend Yield
  • ELVN N/A
  • FSCO 11.44%
  • EPS Growth
  • ELVN N/A
  • FSCO N/A
  • EPS
  • ELVN N/A
  • FSCO N/A
  • Revenue
  • ELVN N/A
  • FSCO N/A
  • Revenue This Year
  • ELVN N/A
  • FSCO N/A
  • Revenue Next Year
  • ELVN N/A
  • FSCO N/A
  • P/E Ratio
  • ELVN N/A
  • FSCO N/A
  • Revenue Growth
  • ELVN N/A
  • FSCO N/A
  • 52 Week Low
  • ELVN $13.30
  • FSCO $4.08
  • 52 Week High
  • ELVN $30.03
  • FSCO $6.00
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 60.45
  • FSCO 52.75
  • Support Level
  • ELVN $19.38
  • FSCO $7.19
  • Resistance Level
  • ELVN $21.34
  • FSCO $7.34
  • Average True Range (ATR)
  • ELVN 1.27
  • FSCO 0.10
  • MACD
  • ELVN 0.11
  • FSCO -0.01
  • Stochastic Oscillator
  • ELVN 88.47
  • FSCO 50.00

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

About FSCO FS Credit Opportunities Corp.

FS Credit Opportunities Corp is a closed-end management investment company. The Fund's primary investment objective is to generate an attractive total return consisting of a high level of current income and capital appreciation, with a secondary objective of capital preservation. It predominantly invests in a portfolio of secured and unsecured floating and fixed-rate loans, bonds, and other types of credit instruments. The credit instruments in which it invests typically are rated below investment grade by rating agencies or would be rated below investment grade if rated. To achieve its investment objectives, the fund focuses on strategies such as Opportunistic Credit, Special Situations, and Capital Structure Solutions.

Share on Social Networks: